Clinical

Dataset Information

Randomized Phase III of PRRT Versus Interferon


ABSTRACT: The purpose of this study is to assess the benefit of 177Lu-DOTATATE versus interferon α-2b in patients with progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues, in terms of disease control.

DISEASE(S): Neuroendocrine Tumors,Gastro-intestinal Neuroendocrine Tumors,Neuroendocrine Tumour,Progressive, Unresectable, Non-pancreatic Gastrointestinal Neuroendocrine Tumors Resistant To Therapy With Somatostatin Analogues.

PROVIDER: 2145354 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR